Nevertheless, in both SCN4 and GSD1b, neutropenia can be alleviated by oral SGLT‐2 inhibitor therapy, which inhibits the renal reabsorption of 1,5‐AHG, effectively decreasing intracellular 1,5‐AHG6P concentrations [15, 16, 17, 18, 19]. Here, SLC37A4 is linked to neutropenia.